Two Versus Five-Fraction Magnetic Resonance-Guided Adaptive Radiotherapy with DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2): Interim Acute Toxicity Analysis of the Phase II Randomised Trial

This publication has 27 references indexed in Scilit:

• Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial “GIVE ME FIVE”
  World Journal of Urology, 2024
• Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review
  World Journal of Urology, 2024
• Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging–Guided Adaptive Prostate Radiation Therapy
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
• Linac-based versus MR-guided SBRT for localized prostate cancer: a comparative evaluation of acute tolerability
  La radiologia medica, 2023
• Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer
  JAMA Oncology, 2023
• Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion
  European Urology Oncology, 2022
• HERMES: Delivery of a Speedy Prostate Cancer Treatment
  Clinical Oncology, 2022
• Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2
  European Urology, 2019
• Radiotherapy Boost for the Dominant Intraprostatic Cancer Lesion—A Systematic Review and Meta-Analysis
  Clinical Genitourinary Cancer, 2016
• Does Local Recurrence of Prostate Cancer After Radiation Therapy Occur at the Site of Primary Tumor? Results of a Longitudinal MRI and MRSI Study
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012